177760-52-0 Usage
Description
ETHYL 2-AMINOOXAZOLE-4-CARBOXYLATE is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals. It is characterized by its unique chemical structure, which allows it to be a versatile building block in the development of new drugs.
Uses
Used in Pharmaceutical Industry:
ETHYL 2-AMINOOXAZOLE-4-CARBOXYLATE is used as an intermediate for the preparation of inhibitors of Akt activity. These inhibitors are valuable in the treatment of various diseases, including cancer and arthritis. By targeting the Akt pathway, these inhibitors can help regulate cellular processes and potentially slow down the progression of these diseases.
Used in Cancer Treatment:
ETHYL 2-AMINOOXAZOLE-4-CARBOXYLATE is used as a key component in the development of drugs that inhibit Akt activity, which plays a significant role in the regulation of cell survival, growth, and angiogenesis. Inhibiting Akt activity can help prevent the uncontrolled cell proliferation associated with cancer, making it a promising approach in the treatment of various types of cancer.
Used in Arthritis Treatment:
In addition to its application in cancer treatment, ETHYL 2-AMINOOXAZOLE-4-CARBOXYLATE is also used in the development of drugs for arthritis. Akt inhibitors derived from this intermediate can help modulate the inflammatory response and reduce the pain and swelling associated with arthritis, providing relief for patients suffering from this condition.
Check Digit Verification of cas no
The CAS Registry Mumber 177760-52-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,7,7,6 and 0 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 177760-52:
(8*1)+(7*7)+(6*7)+(5*7)+(4*6)+(3*0)+(2*5)+(1*2)=170
170 % 10 = 0
So 177760-52-0 is a valid CAS Registry Number.
InChI:InChI=1/C6H8N2O3/c1-2-10-5(9)4-3-11-6(7)8-4/h3H,2H2,1H3,(H2,7,8)
177760-52-0Relevant articles and documents
NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1
-
Page/Page column 172-173, (2020/12/11)
An object of the invention is to provide compounds as selective JAK1 inhibitor, a process for preparation of the inhibitors, a composition containing the compounds and utility of the compounds.
ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS
-
Paragraph 00382, (2017/02/24)
The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.
Tuning and predicting biological affinity: Aryl nitriles as cysteine protease inhibitors
Ehmke, Veronika,Quinsaat, Jose Enrico Q.,Rivera-Fuentes, Pablo,Heindl, Cornelia,Freymond, Céline,Rottmann, Matthias,Brun, Reto,Schirmeister, Tanja,Diederich, Fran?ois
supporting information; experimental part, p. 5764 - 5768 (2012/08/28)
A series of aryl nitrile-based ligands were prepared to investigate the effect of their electrophilicity on the affinity against the cysteine proteases rhodesain and human cathepsin L. Density functional theory calculations provided relative reactivities of the nitriles, enabling prediction of their biological affinity and cytotoxicity and a clear structure-activity relationship.
